Harish CFA - Cymabay Therapeu Chief Officer
Executive
Harish CFA is Chief Officer of Cymabay Therapeu
| Age | 42 |
| Phone | 510 293 8800 |
| Web | https://www.cymabay.com |
Cymabay Therapeu Management Efficiency
The company has return on total asset (ROA) of (0.2205) % which means that it has lost $0.2205 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6417) %, meaning that it created substantial loss on money invested by shareholders. Cymabay Therapeu's management efficiency ratios could be used to measure how well Cymabay Therapeu manages its routine affairs as well as how well it operates its assets and liabilities.Cymabay Therapeu currently holds 114.49 M in liabilities with Debt to Equity (D/E) ratio of 1.45, which is about average as compared to similar companies. Cymabay Therapeu has a current ratio of 11.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cymabay Therapeu's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Ross Moat | Kiniksa Pharmaceuticals | 43 | |
| Scott Gangloff | Akero Therapeutics | 51 | |
| Francis Sarena | 89bio Inc | 54 | |
| Paul Cocja | Phathom Pharmaceuticals | N/A | |
| Carole Huntsman | Madrigal Pharmaceuticals | 60 | |
| Eric MD | Pliant Therapeutics | 61 | |
| Mario Orlando | Gossamer Bio | N/A | |
| John Schembri | Akero Therapeutics | 63 | |
| Chad Morin | Kiniksa Pharmaceuticals | N/A | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
| Lani Ibarra | Structure Therapeutics American | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Emil MD | Terns Pharmaceuticals | 45 | |
| Shamim MS | Stoke Therapeutics | 65 | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
| Carsten MBA | Kiniksa Pharmaceuticals | 59 | |
| CPA CPA | Viking Therapeutics | 54 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 |
Cymabay Therapeu Leadership Team
Elected by the shareholders, the Cymabay Therapeu's board of directors comprises two types of representatives: Cymabay Therapeu inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cymabay. The board's role is to monitor Cymabay Therapeu's management team and ensure that shareholders' interests are well served. Cymabay Therapeu's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cymabay Therapeu's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Chief Officer | ||
| Paul Quinlan, General Counsel, Corporate Secretary | ||
| Patrick OMara, Senior Development | ||
| Robert Martin, Senior Development | ||
| Sujal Shah, CFO and Secretary | ||
| Klara DickinsonEason, Chief Officer | ||
| MBA MD, Chief Officer | ||
| Ken Boehm, Senior Resources | ||
| Harish CFA, Chief Officer | ||
| Ben Kozub, Head Commercial | ||
| Charles McWherter, Chief Scientific Officer and Sr. VP | ||
| Becki Filice, Senior Leadership | ||
| Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer |
Cymabay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cymabay Therapeu a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (745.58) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 99.49 % | |||
| Number Of Shares Shorted | 5.85 M | |||
| Price To Earning | (8.62) X | |||
| Price To Book | 12.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |